# Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT07680933** · PHASE2 · RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT

## Key facts

- **NCT ID:** NCT07680933
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680933, "Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07680933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*